Physician profile
Shelley Ray
NPI 1447259643
$10,994.54
in general payments reported to CMS, 2019-2025
39 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $845 · 2021: $1,757 · 2022: $1,922 · 2023: $1,834 · 2024: $1,838 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,787 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,786.63 |
| Education | $134.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,603.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $812.59 | 2019-2025 | |
| Lilly USA, LLC | $736.79 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $704.80 | 2019-2024 | |
| Amgen INC. | $679.01 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $644.15 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $559.74 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $450.70 | 2019-2024 | Dupixent |
| Galderma Laboratories, L.P. | $443.44 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Leo Pharma INC. | $416.61 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $359.70 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $325.70 | 2019-2024 | Arazlo, Jublia, Duobrii |
| Dermavant Sciences, INC. | $318.21 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $283.28 | 2019-2023 | Ilumya |
| Incyte Corporation | $263.47 | 2021-2024 | Opzelura |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $231.29 | 2019-2024 | |
| Allergan, INC. | $138.86 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $120.97 | 2022 | |
| Ucb, INC. | $116.56 | 2019-2025 | Bimzelx |
| Epi Health, LLC | $94.78 | 2020-2022 | |
| Celgene Corporation | $89.39 | 2019 | |
| Strata Skin Sciences, INC. | $72.99 | 2022-2024 | Xtrac |
| Dermira, INC. | $66.53 | 2019 | |
| Aclaris Therapeutics, INC. | $66.16 | 2019 | |
| Biofrontera INC. | $51.10 | 2019 | |
| Revance Therapeutics, INC. | $42.02 | 2024 | Daxxify |
| Prugen, INC. Pharmaceuticals | $38.22 | 2019-2020 | |
| Almirall LLC | $33.74 | 2019-2023 | Klisyri |
| Paratek Pharmaceuticals, INC. | $30.42 | 2022-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.38 | 2022-2023 | Spevigo |
| Organon LLC | $24.79 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.88 | 2019 | |
| Verrica Pharmaceuticals INC. | $21.63 | 2023 | Ycanth |
| Sandoz INC. | $20.48 | 2020 | |
| Mayne Pharma Commercial LLC | $19.65 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $17.73 | 2021 | |
| Dusa Pharmaceuticals, INC. | $16.86 | 2019 | |
| Journey Medical Corporation | $15.23 | 2025 | |
| Mission Pharmacal Company | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelley Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.